Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-02-04

AUTHORS

Kostas Delaunay, Julien Edeline, Yan Rolland, Nicolas Lepareur, Sophie Laffont, Xavier Palard, Christelle Bouvry, Samuel Le Sourd, Marc Pracht, Valérie Ardisson, Nicolas Noiret, Éric Bellissant, Etienne Garin

ABSTRACT

PurposeThis study sought to provide preliminary results on the biodistribution and dosimetry following intra-arterial liver injection of 188Re-SSS Lipiodol on hepatocellular carcinoma patients included in the Phase I Lip-Re 1 study.MethodsResults of the first six patients included are reported. Analysis of the 188Re-SSS Lipiodol biodistribution was based on planar scintigraphic and tomoscintigraphic (SPECT) studies performed at 1, 6, 24, 48, and 72 h post-administration. Quantification in blood, urine, and stool samples was performed. Determination of the tumour to non-tumour uptake ratio (T/NT) was calculated. Absorbed doses to target organs and tumours were evaluated using the MIRD formalism.ResultsThe mean injected activity of 188Re-SSS Lipiodol was 1645 ± 361 MBq. Uptakes were seen in the liver (tumour and healthy liver) and the lungs only. All these uptakes were stable over time. A mean 1.4 ± 0.7% of 188Re-SSS Lipiodol administered was detected in serum samples at 6 h, declining rapidly thereafter. On average, 1.5 ± 1.6% of administered activity was eliminated in urine and feces over 72 h. Overall, 90.7 ± 1.6% of detected activity on SPECT studies was found in the liver (74.9 ± 1.8% in tumours and 19.1 ± 1.7% in the healthy liver) and 9.3 ± 1.6% in the lungs (5.7 ± 1.1% in right and 3.7 ± 0.5% in left lungs). Mean doses absorbed were 7.9 ± 3.7Gy to the whole liver, 42.7 ± 34.0Gy to the tumours, 10.2 ± 3.7Gy to the healthy liver, and 1.5 ± 1.2Gy to the lungs. Four patients had stable disease on CT scans at 2 months. The first patient with rapidly progressive disease died at 1 month, most probably of massive tumour progression. Due to this early death and using a conservative approach, the trial independent evaluation committee decided to consider this event as a treatment-related toxicity.Conclusion188Re-SSS Lipiodol has a favorable biodistribution profile concerning radioembolization, with the highest in-vivo stability among all radiolabeled Lipiodol compounds reported to date. These preliminary results must be further confirmed while completing this Phase I Lip Re1 study. More... »

PAGES

1506-1517

References to SciGraph publications

  • 2005-12-07. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2003-12-23. Development and biodistribution of 188Re-SSS lipiodol following injection into the hepatic artery of healthy pigs in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s00259-019-04277-9

    DOI

    http://dx.doi.org/10.1007/s00259-019-04277-9

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1111911785

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/30715571


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Carcinoma, Hepatocellular", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Disease Progression", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Combinations", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Embolization, Therapeutic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Injections, Intra-Arterial", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Iodized Oil", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Liver", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Liver Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Lung", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Organometallic Compounds", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Prospective Studies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Radiometry", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Radiopharmaceuticals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tissue Distribution", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tomography, Emission-Computed, Single-Photon", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tomography, X-Ray Computed", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "University of Rennes 1, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.410368.8", 
              "name": [
                "Department of Nuclear Medicine, Cancer Institute Eug\u00e8ne Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes, cedex, France", 
                "University of Rennes 1, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Delaunay", 
            "givenName": "Kostas", 
            "id": "sg:person.016057404645.17", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016057404645.17"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "INSERM INRA UMR 1241 NuMeCan, University of Rennes 1, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.410368.8", 
              "name": [
                "University of Rennes 1, Rennes, France", 
                "Department of Medical Oncology, Cancer Institute Eug\u00e8ne Marquis, Rennes, France", 
                "INSERM INRA UMR 1241 NuMeCan, University of Rennes 1, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Edeline", 
            "givenName": "Julien", 
            "id": "sg:person.0657306623.46", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0657306623.46"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "INSERM UMR 1099 LTSI, University of Rennes 1, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.410368.8", 
              "name": [
                "Department of Medical Imaging, Cancer Institute Eug\u00e8ne Marquis, Rennes, France", 
                "INSERM UMR 1099 LTSI, University of Rennes 1, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Rolland", 
            "givenName": "Yan", 
            "id": "sg:person.0641627157.44", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0641627157.44"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Radiopharmacy, Cancer Institute Eug\u00e8ne Marquis, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.417988.b", 
              "name": [
                "INSERM INRA UMR 1241 NuMeCan, University of Rennes 1, Rennes, France", 
                "Radiopharmacy, Cancer Institute Eug\u00e8ne Marquis, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lepareur", 
            "givenName": "Nicolas", 
            "id": "sg:person.01276035557.58", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276035557.58"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Nuclear Medicine, Cancer Institute Eug\u00e8ne Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes, cedex, France", 
              "id": "http://www.grid.ac/institutes/grid.417988.b", 
              "name": [
                "Department of Nuclear Medicine, Cancer Institute Eug\u00e8ne Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes, cedex, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Laffont", 
            "givenName": "Sophie", 
            "id": "sg:person.0613252755.07", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0613252755.07"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Rennes 1, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.410368.8", 
              "name": [
                "Department of Nuclear Medicine, Cancer Institute Eug\u00e8ne Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes, cedex, France", 
                "University of Rennes 1, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Palard", 
            "givenName": "Xavier", 
            "id": "sg:person.0704702656.95", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704702656.95"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Radiopharmacy, Cancer Institute Eug\u00e8ne Marquis, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.417988.b", 
              "name": [
                "Radiopharmacy, Cancer Institute Eug\u00e8ne Marquis, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Bouvry", 
            "givenName": "Christelle", 
            "id": "sg:person.011140724323.05", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011140724323.05"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medical Oncology, Cancer Institute Eug\u00e8ne Marquis, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.417988.b", 
              "name": [
                "Department of Medical Oncology, Cancer Institute Eug\u00e8ne Marquis, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Le Sourd", 
            "givenName": "Samuel", 
            "id": "sg:person.01110132160.38", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110132160.38"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medical Oncology, Cancer Institute Eug\u00e8ne Marquis, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.417988.b", 
              "name": [
                "Department of Medical Oncology, Cancer Institute Eug\u00e8ne Marquis, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Pracht", 
            "givenName": "Marc", 
            "id": "sg:person.01363611400.69", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363611400.69"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Radiopharmacy, Cancer Institute Eug\u00e8ne Marquis, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.417988.b", 
              "name": [
                "Radiopharmacy, Cancer Institute Eug\u00e8ne Marquis, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ardisson", 
            "givenName": "Val\u00e9rie", 
            "id": "sg:person.01071602521.66", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071602521.66"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "ENSCR, CNRS, ISCR [(Institut des Sciences Chimiques de Rennes)] - UMR 6226, University of Rennes, F-35000, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.410368.8", 
              "name": [
                "ENSCR, CNRS, ISCR [(Institut des Sciences Chimiques de Rennes)] - UMR 6226, University of Rennes, F-35000, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Noiret", 
            "givenName": "Nicolas", 
            "id": "sg:person.0672626707.15", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672626707.15"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Clinical and Biological Pharmacology and Pharmacovigilance, Pharmaco-epidemiology and Drug Information Center, Rennes University Hospital, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.411154.4", 
              "name": [
                "University of Rennes 1, Rennes, France", 
                "INSERM CIC 1414 Clinical Investigation Center, Rennes, France", 
                "Department of Clinical and Biological Pharmacology and Pharmacovigilance, Pharmaco-epidemiology and Drug Information Center, Rennes University Hospital, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Bellissant", 
            "givenName": "\u00c9ric", 
            "id": "sg:person.01115151652.22", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115151652.22"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "INSERM INRA UMR 1241 NuMeCan, University of Rennes 1, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.410368.8", 
              "name": [
                "Department of Nuclear Medicine, Cancer Institute Eug\u00e8ne Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes, cedex, France", 
                "University of Rennes 1, Rennes, France", 
                "INSERM INRA UMR 1241 NuMeCan, University of Rennes 1, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Garin", 
            "givenName": "Etienne", 
            "id": "sg:person.0620512077.06", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0620512077.06"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s00259-003-1402-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1002756691", 
              "https://doi.org/10.1007/s00259-003-1402-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-005-1954-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050009698", 
              "https://doi.org/10.1007/s00259-005-1954-1"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2019-02-04", 
        "datePublishedReg": "2019-02-04", 
        "description": "PurposeThis study sought to provide preliminary results on the biodistribution and dosimetry following intra-arterial liver injection of 188Re-SSS Lipiodol on hepatocellular carcinoma patients included in the Phase I Lip-Re 1 study.MethodsResults of the first six patients included are reported. Analysis of the 188Re-SSS Lipiodol biodistribution was based on planar scintigraphic and tomoscintigraphic (SPECT) studies performed at 1, 6, 24, 48, and 72\u00a0h post-administration. Quantification in blood, urine, and stool samples was performed. Determination of the tumour to non-tumour uptake ratio (T/NT) was calculated. Absorbed doses to target organs and tumours were evaluated using the MIRD formalism.ResultsThe mean injected activity of 188Re-SSS Lipiodol was 1645\u2009\u00b1\u2009361\u00a0MBq. Uptakes were seen in the liver (tumour and healthy liver) and the lungs only. All these uptakes were stable over time. A mean 1.4\u2009\u00b1\u20090.7% of 188Re-SSS Lipiodol administered was detected in serum samples at 6\u00a0h, declining rapidly thereafter. On average, 1.5\u2009\u00b1\u20091.6% of administered activity was eliminated in urine and feces over 72\u00a0h. Overall, 90.7\u2009\u00b1\u20091.6% of detected activity on SPECT studies was found in the liver (74.9\u2009\u00b1\u20091.8% in tumours and 19.1\u2009\u00b1\u20091.7% in the healthy liver) and 9.3\u2009\u00b1\u20091.6% in the lungs (5.7\u2009\u00b1\u20091.1% in right and 3.7\u2009\u00b1\u20090.5% in left lungs). Mean doses absorbed were 7.9\u2009\u00b1\u20093.7Gy to the whole liver, 42.7\u2009\u00b1\u200934.0Gy to the tumours, 10.2\u2009\u00b1\u20093.7Gy to the healthy liver, and 1.5\u2009\u00b1\u20091.2Gy to the lungs. Four patients had stable disease on CT scans at 2\u00a0months. The first patient with rapidly progressive disease died at 1\u00a0month, most probably of massive tumour progression. Due to this early death and using a conservative approach, the trial independent evaluation committee decided to consider this event as a treatment-related toxicity.Conclusion188Re-SSS Lipiodol has a favorable biodistribution profile concerning radioembolization, with the highest in-vivo stability among all radiolabeled Lipiodol compounds reported to date. These preliminary results must be further confirmed while completing this Phase I Lip Re1 study.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s00259-019-04277-9", 
        "inLanguage": "en", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1297401", 
            "issn": [
              "1619-7070", 
              "1619-7089"
            ], 
            "name": "European Journal of Nuclear Medicine and Molecular Imaging", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "7", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "46"
          }
        ], 
        "keywords": [
          "hepatocellular carcinoma patients", 
          "carcinoma patients", 
          "massive tumor progression", 
          "treatment-related toxicity", 
          "favorable biodistribution profile", 
          "stable disease", 
          "progressive disease", 
          "first patient", 
          "liver injection", 
          "mean doses", 
          "clinical trials", 
          "stool samples", 
          "administered activity", 
          "CT scan", 
          "healthy liver", 
          "early death", 
          "patients", 
          "SPECT studies", 
          "injected activity", 
          "PurposeThis study", 
          "tumor progression", 
          "Lipiodol", 
          "whole liver", 
          "serum samples", 
          "MIRD formalism", 
          "phase I", 
          "lung", 
          "liver", 
          "tumors", 
          "uptake ratio", 
          "conservative approach", 
          "biodistribution profile", 
          "radioembolization", 
          "biodistribution", 
          "disease", 
          "doses", 
          "months", 
          "urine", 
          "dosimetry assessment", 
          "vivo stability", 
          "preliminary results", 
          "Evaluation Committee", 
          "study", 
          "blood", 
          "activity", 
          "uptake", 
          "MethodsResults", 
          "progression", 
          "trials", 
          "MBq", 
          "death", 
          "scans", 
          "injection", 
          "organs", 
          "feces", 
          "toxicity", 
          "assessment", 
          "samples", 
          "Committee", 
          "results", 
          "events", 
          "dosimetry", 
          "date", 
          "profile", 
          "quantification", 
          "ratio", 
          "time", 
          "analysis", 
          "compounds", 
          "approach", 
          "determination", 
          "stability", 
          "planar", 
          "formalism", 
          "intra-arterial liver injection", 
          "Phase I Lip-Re 1 study", 
          "I Lip-Re 1 study", 
          "Lip-Re 1 study", 
          "Lipiodol biodistribution", 
          "tomoscintigraphic (SPECT) studies", 
          "non-tumour uptake ratio", 
          "trial independent evaluation committee", 
          "independent evaluation committee", 
          "SSS Lipiodol", 
          "Lipiodol compounds", 
          "Phase 1 Lip-Re I clinical trial", 
          "Lip-Re I clinical trial", 
          "I clinical trial", 
          "Lipiodol radioembolization"
        ], 
        "name": "Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization", 
        "pagination": "1506-1517", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1111911785"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s00259-019-04277-9"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "30715571"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s00259-019-04277-9", 
          "https://app.dimensions.ai/details/publication/pub.1111911785"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2021-12-01T19:45", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_808.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s00259-019-04277-9"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00259-019-04277-9'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00259-019-04277-9'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00259-019-04277-9'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00259-019-04277-9'


     

    This table displays all metadata directly associated to this object as RDF triples.

    349 TRIPLES      22 PREDICATES      138 URIs      128 LITERALS      28 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s00259-019-04277-9 schema:about N089e20d9649042fcaf9312c37f14983c
    2 N118311a18ef644678eb2ff9b42aac0f5
    3 N135e6778f2c547cd9e992f82b42ba691
    4 N1c6052a85b994eda91129b949c14bae3
    5 N1d90a75a798c402584e0fec902ab067a
    6 N2572bc4c081b4217a175398ed6a3aa3b
    7 N38833203cd0f499ba7dc7a5c73457be9
    8 N3a39774863b8401c9e47034a1a2c0c4b
    9 N4846f19627e549af93a34b64233e2efa
    10 N500af00f17074964acf0903686be04e7
    11 N54003e90613a4206870100f51407e2ed
    12 N62893fab5da94a428089ada442c7a2ed
    13 N701f19a4ab4b422e85bbd488d58b748c
    14 N8313a5b9e051492bb3393bc8a9a72a03
    15 N9514e2b212734472869a42f34b7393c8
    16 Nb2bcdba9e1c045399992efd9486877ba
    17 Nce23859551874364b3100eee71da4269
    18 Nd73efcfcc84d437d8c34761c6320cfb8
    19 Ndf1ae332e7c14d15b12405b92851980c
    20 Nf0ef1e1088f0477fb3a368b166e714b4
    21 Nf4730c66d14f49e187cd2fc5bf59b2ff
    22 anzsrc-for:11
    23 anzsrc-for:1103
    24 schema:author N6cde6787a84f4d9a9974b38334025936
    25 schema:citation sg:pub.10.1007/s00259-003-1402-z
    26 sg:pub.10.1007/s00259-005-1954-1
    27 schema:datePublished 2019-02-04
    28 schema:datePublishedReg 2019-02-04
    29 schema:description PurposeThis study sought to provide preliminary results on the biodistribution and dosimetry following intra-arterial liver injection of 188Re-SSS Lipiodol on hepatocellular carcinoma patients included in the Phase I Lip-Re 1 study.MethodsResults of the first six patients included are reported. Analysis of the 188Re-SSS Lipiodol biodistribution was based on planar scintigraphic and tomoscintigraphic (SPECT) studies performed at 1, 6, 24, 48, and 72 h post-administration. Quantification in blood, urine, and stool samples was performed. Determination of the tumour to non-tumour uptake ratio (T/NT) was calculated. Absorbed doses to target organs and tumours were evaluated using the MIRD formalism.ResultsThe mean injected activity of 188Re-SSS Lipiodol was 1645 ± 361 MBq. Uptakes were seen in the liver (tumour and healthy liver) and the lungs only. All these uptakes were stable over time. A mean 1.4 ± 0.7% of 188Re-SSS Lipiodol administered was detected in serum samples at 6 h, declining rapidly thereafter. On average, 1.5 ± 1.6% of administered activity was eliminated in urine and feces over 72 h. Overall, 90.7 ± 1.6% of detected activity on SPECT studies was found in the liver (74.9 ± 1.8% in tumours and 19.1 ± 1.7% in the healthy liver) and 9.3 ± 1.6% in the lungs (5.7 ± 1.1% in right and 3.7 ± 0.5% in left lungs). Mean doses absorbed were 7.9 ± 3.7Gy to the whole liver, 42.7 ± 34.0Gy to the tumours, 10.2 ± 3.7Gy to the healthy liver, and 1.5 ± 1.2Gy to the lungs. Four patients had stable disease on CT scans at 2 months. The first patient with rapidly progressive disease died at 1 month, most probably of massive tumour progression. Due to this early death and using a conservative approach, the trial independent evaluation committee decided to consider this event as a treatment-related toxicity.Conclusion188Re-SSS Lipiodol has a favorable biodistribution profile concerning radioembolization, with the highest in-vivo stability among all radiolabeled Lipiodol compounds reported to date. These preliminary results must be further confirmed while completing this Phase I Lip Re1 study.
    30 schema:genre article
    31 schema:inLanguage en
    32 schema:isAccessibleForFree false
    33 schema:isPartOf N1e70b769b9c24f5bbfc14d95f744c86d
    34 N9455b5413152420590f4ad822046d6aa
    35 sg:journal.1297401
    36 schema:keywords CT scan
    37 Committee
    38 Evaluation Committee
    39 I Lip-Re 1 study
    40 I clinical trial
    41 Lip-Re 1 study
    42 Lip-Re I clinical trial
    43 Lipiodol
    44 Lipiodol biodistribution
    45 Lipiodol compounds
    46 Lipiodol radioembolization
    47 MBq
    48 MIRD formalism
    49 MethodsResults
    50 Phase 1 Lip-Re I clinical trial
    51 Phase I Lip-Re 1 study
    52 PurposeThis study
    53 SPECT studies
    54 SSS Lipiodol
    55 activity
    56 administered activity
    57 analysis
    58 approach
    59 assessment
    60 biodistribution
    61 biodistribution profile
    62 blood
    63 carcinoma patients
    64 clinical trials
    65 compounds
    66 conservative approach
    67 date
    68 death
    69 determination
    70 disease
    71 doses
    72 dosimetry
    73 dosimetry assessment
    74 early death
    75 events
    76 favorable biodistribution profile
    77 feces
    78 first patient
    79 formalism
    80 healthy liver
    81 hepatocellular carcinoma patients
    82 independent evaluation committee
    83 injected activity
    84 injection
    85 intra-arterial liver injection
    86 liver
    87 liver injection
    88 lung
    89 massive tumor progression
    90 mean doses
    91 months
    92 non-tumour uptake ratio
    93 organs
    94 patients
    95 phase I
    96 planar
    97 preliminary results
    98 profile
    99 progression
    100 progressive disease
    101 quantification
    102 radioembolization
    103 ratio
    104 results
    105 samples
    106 scans
    107 serum samples
    108 stability
    109 stable disease
    110 stool samples
    111 study
    112 time
    113 tomoscintigraphic (SPECT) studies
    114 toxicity
    115 treatment-related toxicity
    116 trial independent evaluation committee
    117 trials
    118 tumor progression
    119 tumors
    120 uptake
    121 uptake ratio
    122 urine
    123 vivo stability
    124 whole liver
    125 schema:name Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization
    126 schema:pagination 1506-1517
    127 schema:productId N4af22bff50be4e7e8e9b4067e559804e
    128 N59ca357073bc407b9b199245440a1044
    129 Nba758627ac27474586ba109dfb04ac4f
    130 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111911785
    131 https://doi.org/10.1007/s00259-019-04277-9
    132 schema:sdDatePublished 2021-12-01T19:45
    133 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    134 schema:sdPublisher Nc22bebf74d3a47bfafa115397f48a577
    135 schema:url https://doi.org/10.1007/s00259-019-04277-9
    136 sgo:license sg:explorer/license/
    137 sgo:sdDataset articles
    138 rdf:type schema:ScholarlyArticle
    139 N089e20d9649042fcaf9312c37f14983c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    140 schema:name Middle Aged
    141 rdf:type schema:DefinedTerm
    142 N0b511e7cacc04aa9be0619b78201a8f7 rdf:first sg:person.0613252755.07
    143 rdf:rest N28fbba5dc2844004aa974a4c3c1c1d41
    144 N0ce360d52bd44d3fb50cf8ee6c82312c rdf:first sg:person.01115151652.22
    145 rdf:rest N7dbc4d9f8aee48b78c4ff64ef98bbc0a
    146 N118311a18ef644678eb2ff9b42aac0f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    147 schema:name Injections, Intra-Arterial
    148 rdf:type schema:DefinedTerm
    149 N135e6778f2c547cd9e992f82b42ba691 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    150 schema:name Female
    151 rdf:type schema:DefinedTerm
    152 N1c6052a85b994eda91129b949c14bae3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    153 schema:name Lung
    154 rdf:type schema:DefinedTerm
    155 N1d90a75a798c402584e0fec902ab067a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    156 schema:name Prospective Studies
    157 rdf:type schema:DefinedTerm
    158 N1e70b769b9c24f5bbfc14d95f744c86d schema:issueNumber 7
    159 rdf:type schema:PublicationIssue
    160 N2572bc4c081b4217a175398ed6a3aa3b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    161 schema:name Radiopharmaceuticals
    162 rdf:type schema:DefinedTerm
    163 N28fbba5dc2844004aa974a4c3c1c1d41 rdf:first sg:person.0704702656.95
    164 rdf:rest N88d550a807914664a07d86884d411057
    165 N2e012a9bee654cb1bcc8618062103658 rdf:first sg:person.01363611400.69
    166 rdf:rest Nf4c0b164560d4272bbba35de6d969788
    167 N2fce681488154dbbaebeda459c142b50 rdf:first sg:person.01110132160.38
    168 rdf:rest N2e012a9bee654cb1bcc8618062103658
    169 N38833203cd0f499ba7dc7a5c73457be9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    170 schema:name Tomography, Emission-Computed, Single-Photon
    171 rdf:type schema:DefinedTerm
    172 N3a39774863b8401c9e47034a1a2c0c4b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    173 schema:name Liver Neoplasms
    174 rdf:type schema:DefinedTerm
    175 N4846f19627e549af93a34b64233e2efa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    176 schema:name Carcinoma, Hepatocellular
    177 rdf:type schema:DefinedTerm
    178 N4af22bff50be4e7e8e9b4067e559804e schema:name pubmed_id
    179 schema:value 30715571
    180 rdf:type schema:PropertyValue
    181 N500af00f17074964acf0903686be04e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    182 schema:name Humans
    183 rdf:type schema:DefinedTerm
    184 N54003e90613a4206870100f51407e2ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    185 schema:name Organometallic Compounds
    186 rdf:type schema:DefinedTerm
    187 N59ca357073bc407b9b199245440a1044 schema:name doi
    188 schema:value 10.1007/s00259-019-04277-9
    189 rdf:type schema:PropertyValue
    190 N62893fab5da94a428089ada442c7a2ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    191 schema:name Embolization, Therapeutic
    192 rdf:type schema:DefinedTerm
    193 N6cde6787a84f4d9a9974b38334025936 rdf:first sg:person.016057404645.17
    194 rdf:rest Nb3bc7b2e38ce47b192a32290a3bd238d
    195 N701f19a4ab4b422e85bbd488d58b748c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    196 schema:name Liver
    197 rdf:type schema:DefinedTerm
    198 N710ebc8f1a3a44ff9226aa022a3f9071 rdf:first sg:person.0672626707.15
    199 rdf:rest N0ce360d52bd44d3fb50cf8ee6c82312c
    200 N7dbc4d9f8aee48b78c4ff64ef98bbc0a rdf:first sg:person.0620512077.06
    201 rdf:rest rdf:nil
    202 N8313a5b9e051492bb3393bc8a9a72a03 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    203 schema:name Tissue Distribution
    204 rdf:type schema:DefinedTerm
    205 N88d550a807914664a07d86884d411057 rdf:first sg:person.011140724323.05
    206 rdf:rest N2fce681488154dbbaebeda459c142b50
    207 N9455b5413152420590f4ad822046d6aa schema:volumeNumber 46
    208 rdf:type schema:PublicationVolume
    209 N9514e2b212734472869a42f34b7393c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    210 schema:name Male
    211 rdf:type schema:DefinedTerm
    212 Nb2bcdba9e1c045399992efd9486877ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    213 schema:name Drug Combinations
    214 rdf:type schema:DefinedTerm
    215 Nb3bc7b2e38ce47b192a32290a3bd238d rdf:first sg:person.0657306623.46
    216 rdf:rest Ne9de3bc6b33d422ea3ef7a80c8592b70
    217 Nba758627ac27474586ba109dfb04ac4f schema:name dimensions_id
    218 schema:value pub.1111911785
    219 rdf:type schema:PropertyValue
    220 Nc22bebf74d3a47bfafa115397f48a577 schema:name Springer Nature - SN SciGraph project
    221 rdf:type schema:Organization
    222 Nce23859551874364b3100eee71da4269 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    223 schema:name Radiometry
    224 rdf:type schema:DefinedTerm
    225 Nd73efcfcc84d437d8c34761c6320cfb8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    226 schema:name Aged
    227 rdf:type schema:DefinedTerm
    228 Ndf1ae332e7c14d15b12405b92851980c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    229 schema:name Iodized Oil
    230 rdf:type schema:DefinedTerm
    231 Ne9de3bc6b33d422ea3ef7a80c8592b70 rdf:first sg:person.0641627157.44
    232 rdf:rest Necfe626542414e4faa9f2d4957ab658f
    233 Necfe626542414e4faa9f2d4957ab658f rdf:first sg:person.01276035557.58
    234 rdf:rest N0b511e7cacc04aa9be0619b78201a8f7
    235 Nf0ef1e1088f0477fb3a368b166e714b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    236 schema:name Tomography, X-Ray Computed
    237 rdf:type schema:DefinedTerm
    238 Nf4730c66d14f49e187cd2fc5bf59b2ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    239 schema:name Disease Progression
    240 rdf:type schema:DefinedTerm
    241 Nf4c0b164560d4272bbba35de6d969788 rdf:first sg:person.01071602521.66
    242 rdf:rest N710ebc8f1a3a44ff9226aa022a3f9071
    243 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    244 schema:name Medical and Health Sciences
    245 rdf:type schema:DefinedTerm
    246 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    247 schema:name Clinical Sciences
    248 rdf:type schema:DefinedTerm
    249 sg:journal.1297401 schema:issn 1619-7070
    250 1619-7089
    251 schema:name European Journal of Nuclear Medicine and Molecular Imaging
    252 schema:publisher Springer Nature
    253 rdf:type schema:Periodical
    254 sg:person.01071602521.66 schema:affiliation grid-institutes:grid.417988.b
    255 schema:familyName Ardisson
    256 schema:givenName Valérie
    257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071602521.66
    258 rdf:type schema:Person
    259 sg:person.01110132160.38 schema:affiliation grid-institutes:grid.417988.b
    260 schema:familyName Le Sourd
    261 schema:givenName Samuel
    262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110132160.38
    263 rdf:type schema:Person
    264 sg:person.011140724323.05 schema:affiliation grid-institutes:grid.417988.b
    265 schema:familyName Bouvry
    266 schema:givenName Christelle
    267 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011140724323.05
    268 rdf:type schema:Person
    269 sg:person.01115151652.22 schema:affiliation grid-institutes:grid.411154.4
    270 schema:familyName Bellissant
    271 schema:givenName Éric
    272 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115151652.22
    273 rdf:type schema:Person
    274 sg:person.01276035557.58 schema:affiliation grid-institutes:grid.417988.b
    275 schema:familyName Lepareur
    276 schema:givenName Nicolas
    277 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276035557.58
    278 rdf:type schema:Person
    279 sg:person.01363611400.69 schema:affiliation grid-institutes:grid.417988.b
    280 schema:familyName Pracht
    281 schema:givenName Marc
    282 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363611400.69
    283 rdf:type schema:Person
    284 sg:person.016057404645.17 schema:affiliation grid-institutes:grid.410368.8
    285 schema:familyName Delaunay
    286 schema:givenName Kostas
    287 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016057404645.17
    288 rdf:type schema:Person
    289 sg:person.0613252755.07 schema:affiliation grid-institutes:grid.417988.b
    290 schema:familyName Laffont
    291 schema:givenName Sophie
    292 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0613252755.07
    293 rdf:type schema:Person
    294 sg:person.0620512077.06 schema:affiliation grid-institutes:grid.410368.8
    295 schema:familyName Garin
    296 schema:givenName Etienne
    297 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0620512077.06
    298 rdf:type schema:Person
    299 sg:person.0641627157.44 schema:affiliation grid-institutes:grid.410368.8
    300 schema:familyName Rolland
    301 schema:givenName Yan
    302 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0641627157.44
    303 rdf:type schema:Person
    304 sg:person.0657306623.46 schema:affiliation grid-institutes:grid.410368.8
    305 schema:familyName Edeline
    306 schema:givenName Julien
    307 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0657306623.46
    308 rdf:type schema:Person
    309 sg:person.0672626707.15 schema:affiliation grid-institutes:grid.410368.8
    310 schema:familyName Noiret
    311 schema:givenName Nicolas
    312 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672626707.15
    313 rdf:type schema:Person
    314 sg:person.0704702656.95 schema:affiliation grid-institutes:grid.410368.8
    315 schema:familyName Palard
    316 schema:givenName Xavier
    317 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704702656.95
    318 rdf:type schema:Person
    319 sg:pub.10.1007/s00259-003-1402-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1002756691
    320 https://doi.org/10.1007/s00259-003-1402-z
    321 rdf:type schema:CreativeWork
    322 sg:pub.10.1007/s00259-005-1954-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050009698
    323 https://doi.org/10.1007/s00259-005-1954-1
    324 rdf:type schema:CreativeWork
    325 grid-institutes:grid.410368.8 schema:alternateName ENSCR, CNRS, ISCR [(Institut des Sciences Chimiques de Rennes)] - UMR 6226, University of Rennes, F-35000, Rennes, France
    326 INSERM INRA UMR 1241 NuMeCan, University of Rennes 1, Rennes, France
    327 INSERM UMR 1099 LTSI, University of Rennes 1, Rennes, France
    328 University of Rennes 1, Rennes, France
    329 schema:name Department of Medical Imaging, Cancer Institute Eugène Marquis, Rennes, France
    330 Department of Medical Oncology, Cancer Institute Eugène Marquis, Rennes, France
    331 Department of Nuclear Medicine, Cancer Institute Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes, cedex, France
    332 ENSCR, CNRS, ISCR [(Institut des Sciences Chimiques de Rennes)] - UMR 6226, University of Rennes, F-35000, Rennes, France
    333 INSERM INRA UMR 1241 NuMeCan, University of Rennes 1, Rennes, France
    334 INSERM UMR 1099 LTSI, University of Rennes 1, Rennes, France
    335 University of Rennes 1, Rennes, France
    336 rdf:type schema:Organization
    337 grid-institutes:grid.411154.4 schema:alternateName Department of Clinical and Biological Pharmacology and Pharmacovigilance, Pharmaco-epidemiology and Drug Information Center, Rennes University Hospital, Rennes, France
    338 schema:name Department of Clinical and Biological Pharmacology and Pharmacovigilance, Pharmaco-epidemiology and Drug Information Center, Rennes University Hospital, Rennes, France
    339 INSERM CIC 1414 Clinical Investigation Center, Rennes, France
    340 University of Rennes 1, Rennes, France
    341 rdf:type schema:Organization
    342 grid-institutes:grid.417988.b schema:alternateName Department of Medical Oncology, Cancer Institute Eugène Marquis, Rennes, France
    343 Department of Nuclear Medicine, Cancer Institute Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes, cedex, France
    344 Radiopharmacy, Cancer Institute Eugène Marquis, Rennes, France
    345 schema:name Department of Medical Oncology, Cancer Institute Eugène Marquis, Rennes, France
    346 Department of Nuclear Medicine, Cancer Institute Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes, cedex, France
    347 INSERM INRA UMR 1241 NuMeCan, University of Rennes 1, Rennes, France
    348 Radiopharmacy, Cancer Institute Eugène Marquis, Rennes, France
    349 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...